|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0054403,
umls-concept:C0144576,
umls-concept:C0178602,
umls-concept:C0183683,
umls-concept:C0205179,
umls-concept:C0205488,
umls-concept:C0300926,
umls-concept:C0344211,
umls-concept:C0750729,
umls-concept:C0936012,
umls-concept:C1140680,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1516213,
umls-concept:C1519249,
umls-concept:C1521721,
umls-concept:C1637379
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1995-6-5
|
|
pubmed:abstractText |
We commenced a phase I study of escalating dose Taxol (paclitaxel; Bristol-Myers Squibb Co, Wallingford, CT) in addition to cyclophosphamide, to assess its impact on both antitumor efficacy and mobilization of peripheral-blood progenitor cells (PBP).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
1160-6
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:7537799-Adenocarcinoma,
pubmed-meshheading:7537799-Adult,
pubmed-meshheading:7537799-Antigens, CD,
pubmed-meshheading:7537799-Antigens, CD34,
pubmed-meshheading:7537799-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7537799-Carboplatin,
pubmed-meshheading:7537799-Cyclophosphamide,
pubmed-meshheading:7537799-Dose-Response Relationship, Drug,
pubmed-meshheading:7537799-Drug Administration Schedule,
pubmed-meshheading:7537799-Female,
pubmed-meshheading:7537799-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:7537799-Humans,
pubmed-meshheading:7537799-Leukocyte Count,
pubmed-meshheading:7537799-Middle Aged,
pubmed-meshheading:7537799-Neoplasm Staging,
pubmed-meshheading:7537799-Ovarian Neoplasms,
pubmed-meshheading:7537799-Paclitaxel,
pubmed-meshheading:7537799-Stem Cells,
pubmed-meshheading:7537799-Treatment Outcome,
pubmed-meshheading:7537799-Tumor Markers, Biological
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
|
|
pubmed:affiliation |
Solid Tumor Division, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
